Core Scientific vs Tucows
Tucows reported revenue of $390 million in fiscal 2025, 1.2 times Core Scientific's $319 million in fiscal 2025. Core Scientific's revenue fell 37.5% in its latest year, and Tucows' grew 7.7%. Core Scientific had an operating margin of -77.0%, against -6.0% at Tucows. Free cash flow was −$451 million at Core Scientific and −$23 million at Tucows.
Side by side
| Core Scientific | Tucows | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $319M | $390M |
| Revenue growth | −37.5% | 7.7% |
| Revenue growth a year, last 5 years | 39.5% | 4.6% |
| Gross margin | 11.9% | 24.1% |
| Operating margin | −77.0% | −6.0% |
| Net margin | −90.5% | −19.4% |
| Free cash flow | −$451M | −$23M |
| Free cash flow margin | −141.3% | −5.9% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 24.3% | 0.9% |
| Last close | $11.76 | $12.69 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $444,000, sold $5.8 million | — |
| Piotroski F-score | — | 4 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Core ScientificTucows
Operating margin
Percent of revenue
Core ScientificTucows
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Core ScientificTucows
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Core Scientific and Tucows pages.